


09/787436

(FILE 'REGISTRY' ENTERED AT 12:53:17 ON 22 NOV 2004)  
L13 STR


Str.



REP G1=(3-3) CH2  
NODE ATTRIBUTES:  
CONNECT IS X2 RC AT 4  
CONNECT IS X2 RC AT 5  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE  
L15 2838 SEA FILE=REGISTRY SSS FUL L13  
L26 STR



NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
GGCAT IS PCY AT 16  
GGCAT IS MCY UNS AT 29  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 36

09/787436

STEREO ATTRIBUTES: NONE

L27 3 SEA FILE=REGISTRY SUB=L15 SSS FUL L26

100.0% PROCESSED 74 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 12:57:42 ON 22 NOV 2004  
L28 3 S L27

L28 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1989:112150 CAPLUS

DOCUMENT NUMBER: 110:112150

TITLE: Luliberin peptide analog for stimulation of production of roe during artificial milting of common tench (Tinca tinca), trout (Micropterus salmoides) and sheatfish (Silurus glanis)

INVENTOR(S): Kouril, Jan; Hamackova, Jitka; Machacek, Jiri; Barth, Tomislav; Flegel, Martin

PATENT ASSIGNEE(S): Czech.

SOURCE: Czech., 8 pp.

CODEN: CZXXA9

DOCUMENT TYPE: Patent

LANGUAGE: Czech

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CS 244397	B1	19860717	CS 1984-8441	19841006
PRIORITY APPLN. INFO.:			CS 1984-8441	19841006

AB A method of obtaining roe during artificial milting of T. tinca, M. salmoides, and S. glanis is characterized by injecting female egg-carrying fish, during premilting maturity, i.m. with Glu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-NH<sub>2</sub> (I), an analog of luliberin, at 5-20 µg/kg. Female egg-carrying tench (500-1000 g, 4-5 yr) at 20-22° were injected i.m. with I (5-80 µg/kg). Within 15 h, the roe were ready for milting. A dosage of 20 µg/kg resulted in ovulation by 62.5% of the fish. The most effective dosage range was 5-20 µg/kg.

IT 119261-01-7



RL: BIOL (Biological study)  
(ovulation stimulation by, in fish)

RN 119261-01-7 CAPLUS

CN Luteinizing hormone-releasing factor (swine), 1-L-glutamic acid-6-D-alanine-9- (N-ethyl-L-prolinamide)-10-deglycinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searcher : Shears 571-272-2528



L28 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 1988:556330 CAPLUS  
 DOCUMENT NUMBER: 109:156330  
 TITLE: Reversed-phase high-performance liquid chromatography  
 of fertirelin acetate and related compounds  
 AUTHOR(S): Hartman, Patrick A.; Stodola, John D.  
 CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA  
 SOURCE: Journal of Chromatography (1988), 444, 177-82  
 CODEN: JOCRAM; ISSN: 0021-9673

DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Separation of fertirelin acetate (FA) from process impurities, potential degradation products and related peptides including LH releasing hormone was achieved by reversed-phase HPLC. A number of chromatog. conditions (column type mobile phase composition, isocratic/gradient elution) and detection systems were utilized to examine the bulk drug and formulation of FA. Examples of sepsns. designed for potency and impurity detns. are described. Complete recovery of FA is obtained with an isocratic HPLC system. An external standard method is used to determine potency with a precision of

<1%

R.S.D. A gradient HPLC system is used to determine impurities with a precision

of 5-10% R.S.D. at the 1-2% impurity level. As little as .apprx.0.1% (area %) of related peptides are detected at 214 nm.

IT 116921-32-5


RL: ANT (Analyte); ANST (Analytical study)  
 (HPLC of, as fertirelin acetate impurity)


RN 116921-32-5 CAPLUS

CN Luteinizing hormone-releasing factor (swine), 1-L-glutamic acid-9-(N-ethyl-L-prolinamide)-10-deglycinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





—NH

L28 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1988:82207 CAPLUS

DOCUMENT NUMBER: 108:82207

TITLE: HPLC of leuprolide acetate in injectable solutions

AUTHOR(S): Sutherland, J. W.; Menon, G. N.

CORPORATE SOURCE: Pharm. Prod. Div., Abbott Lab., North Chicago, IL, 60064, USA

SOURCE: Journal of Liquid Chromatography (1987), 10(10), 2281-9

CODEN: JLCHD8; ISSN: 0148-3919

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A stability-indicating HPLC method based on a 5- $\mu$  octadecylsilane column and pH 6.5 0.057M aqueous monobasic ammonium phosphate solution-MeCN (77:23 by volume) mobile phase, and UV detection at 220 nm was used for the determination of leuprolide acetate in injections. Et p-hydroxybenzoate was the

internal standard The relative standard deviation was 1.8% and the method was

also successfully used for the determination of impurities/precursors occurring

during the drug manufacture The drug was more stable at pH 3.3 than at pH 10.3

when heated at 100° for 16 h. Glul-leuprolide was the major degradation product when the drug was treated with 0.1N HCl at 40° for 48 h.

IT 112642-13-4


RL: ANT (Analyte); ANST (Analytical study)  
(determination of, as leuprolide impurity by HPLC)

RN 112642-13-4 CAPLUS


CN Luteinizing hormone-releasing factor (swine), 1-L-glutamic acid-6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



=NH

FILE 'CAOLD' ENTERED AT 12:58:05 ON 22 NOV 2004  
L29 0 S L27


FILE 'USPATFULL' ENTERED AT 12:58:10 ON 22 NOV 2004  
L30 0 S L27

FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 12:58:19 ON 22 NOV 2004  
L31 0 S L27

Searcher : Shears 571-272-2528

09/787436

(FILE 'MARPAT' ENTERED AT 12:58:35 ON 22 NOV 2004)  
L32 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM  
MLEVEL IS CLASS AT 16 29  
GGCAT IS PCY AT 16  
GGCAT IS MCY UNS AT 29  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:

ECLEVEL IS LIM ON ALL NODES  
ALL RING(S) ARE ISOLATED

L34 92 SEA FILE=MARPAT SSS FUL L32 (MODIFIED ATTRIBUTES)  
L35 STR



REP G1=(3-3) CH2

NODE ATTRIBUTES:

CONNECT IS X2 RC AT 4  
CONNECT IS X2 RC AT 5

Searcher : Shears 571-272-2528

09/787436

DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:  
ECLEVEL IS LIM ON ALL NODES  
ALL RING(S) ARE ISOLATED

L36 6 SEA FILE=MARPAT SUB=L34 SSS FUL L35 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 82 ITERATIONS 6 ANSWERS  
SEARCH TIME: 00.00.01

L36 ANSWER 1 OF 6 MARPAT COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 141:162339 MARPAT  
TITLE: Improved linkers for pharmaceutical compounds  
INVENTOR(S): De Haeen, Christoph; Nunn, Adrian; Swenson, Rolf E.  
PATENT ASSIGNEE(S): Bracco Imaging S.P.A., Italy  
SOURCE: PCT Int. Appl., 122 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062574	A2	20040729	WO 2003-US41656	20031224
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN: INFO.: US 2003-439722P 20030113

AB A new and improved method for extending the half life of pharmaceutical compds. for use in diagnostic imaging or therapy uses a novel linker to attach a diagnostic or therapeutic moiety to a targeting peptide or another diagnostic or therapeutic moiety. The resulting compound may have the general formula M-N-O-P-Q, wherein M is the diagnostic or therapeutic moiety, N-O-P is the linker of the present invention, and Q is the targeting peptide. In another embodiment the compds. may have the formula M-N-O-P-M, wherein M is independently a diagnostic or therapeutic moiety and N-O-P is the linker of the invention. Methods for imaging or treating a patient using the compds. of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound are further provided. Methods for radiotherapy of a patient using the compds. are

Searcher : Shears 571-272-2528



further provided, as are methods for preparing a radiotherapeutic agent from the compds.

IC ICM A61K

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 8, 26, 34

ST imaging agent targeted conjugate prepn bile acid; radiotherapeutic targeted conjugate prepn

IT Imaging agents  
(NMR contrast; targeted diagnostic and therapeutic agents with improved half life)

IT Imaging agents  
(acoustic; targeted diagnostic and therapeutic agents with improved half life)

IT Antibiotics  
(conjugates; targeted diagnostic and therapeutic agents with improved half life)

IT Antibodies and Immunoglobulins  
Interleukin 1  
Neurokinins  
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(conjugates; targeted diagnostic and therapeutic agents with improved half life)

IT Enzymes, biological studies  
Growth factors, animal  
Hormones, animal, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(conjugates; targeted diagnostic and therapeutic agents with improved half life)

IT Drug delivery systems  
(immunoconjugates; targeted diagnostic and therapeutic agents with improved half life)

IT Drug delivery systems  
(injections; targeted diagnostic and therapeutic agents with improved half life)

IT Human  
Imaging agents  
Photodynamic therapy  
Phototherapy  
Radiopharmaceuticals  
Radiotherapy  
Test kits  
(targeted diagnostic and therapeutic agents with improved half life)

IT Amino acids, biological studies  
Bile acids  
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(targeted diagnostic and therapeutic agents with improved half life)

IT 7440-54-2D, Gadolinium, cholic acid and peptide-conjugated complexes  
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)  
(targeted diagnostic and therapeutic agents with improved half life)

IT 721937-44-6DP, Lutetium 177 complexes 721937-46-8DP, Lutetium 177/Indium 111/Gadolinium complexes  
RL: DGN (Diagnostic use); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

- (targeted diagnostic and therapeutic agents with improved half life)
- IT 14265-75-9DP, 177Lu, cholic acid and peptide-conjugated complexes, biological studies  
 RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
- (targeted diagnostic and therapeutic agents with improved half life)
- IT 83-44-3DP, Deoxycholic acid, conjugates 14158-31-7DP, Iodine 125, insulin derivs. labeled with, biological studies 721937-42-4DP, complexes 721937-44-6DP, complexes 721937-46-8DP, complexes 721937-48-0DP, complexes 721937-50-4DP, complexes 721937-52-6DP, complexes 721937-54-8DP, complexes 728038-66-2DP, complexes 728919-39-9DP, Indium 111 complexes  
 RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
- (targeted diagnostic and therapeutic agents with improved half life)
- IT 50-56-6D, Oxytocin, conjugates 58-82-2D, Bradykinin, conjugates 69-79-4D, Maltose, conjugates 113-79-1D, Arginine vasopressin, conjugates 9002-79-3D, MSH, conjugates 9011-97-6D, CCK, conjugates 9034-40-6D, LH-RH, conjugates 15750-15-9D, Indium 111, conjugated complexes, biological studies 33507-63-0D, Substance P, conjugates 37221-79-7D, VIP, conjugates 51110-01-1D, Somatostatin, conjugates 62229-50-9D, EGF, conjugates 82785-45-3D, Neuropeptide Y, conjugates 83150-76-9D, Octreotide, conjugates 106526-69-6D, conjugates 108736-35-2D, Lanreotide, conjugates 116243-73-3D, Endothelin, conjugates 153582-79-7D, conjugates 208253-06-9D, conjugated complexes 455892-74-7D, conjugates 728038-56-0D, conjugates 728038-57-1D, conjugates 728038-58-2D, conjugates 728038-59-3 728912-33-2D, Galanin, conjugates 728919-36-6 728919-37-7 728919-39-9  
 RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (targeted diagnostic and therapeutic agents with improved half life)
- IT 99-33-2 108-30-5, reactions 29022-11-5 38359-38-5 106697-50-1 135053-62-2 157692-53-0 721939-41-9D, resin-bound 721939-45-3 728038-68-4  
 RL: RCT (Reactant); RACT (Reactant or reagent)
- (targeted diagnostic and therapeutic agents with improved half life)
- IT 106526-69-6P 153582-79-7P 455892-74-7P 721939-40-8P 721939-49-7P 721939-52-2P 728038-60-6P 728038-61-7P 728038-63-9P 728038-64-0P 728038-67-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
- (targeted diagnostic and therapeutic agents with improved half life)
- IT 728038-62-8P 728038-65-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)
- (targeted diagnostic and therapeutic agents with improved half life)
- IT 9004-10-8D, Insulin, conjugates  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (targeted diagnostic and therapeutic agents with improved half life)

L36 ANSWER 2 OF 6 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 141:47383 MARPAT

TITLE: Peptides having antiangiogenic activity

INVENTOR(S): Haviv, Fortuna; Henkin, Jack; Bradley, Michael F.;  
 Calvin, Douglas M.; Schneider, Andrew J.

PATENT ASSIGNEE(S): USA

09/787436

SOURCE: U.S., 27 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6753408	B1	20040622	US 2000-718591	20001122
PRIORITY APPLN. INFO.:			US 1999-166791P	19991122
AB	Peptides Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compns. and methods of inhibiting angiogenesis in a mammal. Compds. such as N-Ac-Sar-Gly-Lys(Ac)-D-Leu-Thr-Nva-Ile-Arg-ProNH-Et were prepared The compds. inhibited human endothelial cell migration by at least 50 % inhibition when tested at concns. of 1 nM.			
IC	ICM C07K007-00			
NCL	530328000			
CC	1-12 (Pharmacology) Section cross-reference(s): 34			
ST	antiangiogenic peptide; endothelial cell migration inhibition peptide			
IT	Blood vessel (microvessel, endothelium, inhibition of migration of cells of, of human; peptides having antiangiogenic activity)			
IT	Cell migration (of human microvascular endothelial cells, inhibition of; peptides having antiangiogenic activity)			
IT	Angiogenesis inhibitors Antitumor agents Drug delivery systems Human Mammalia (peptides having antiangiogenic activity)			
IT	Peptides, biological studies RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peptides having antiangiogenic activity)			
IT	341522-16-5P	341522-18-7P	341522-20-1P	341522-22-3P 341522-24-5P
	341522-29-0P	341522-35-8P	341522-37-0P	341522-39-2P 341522-41-6P
	341522-43-8P	341522-45-0P	341522-47-2P	341522-49-4P 341522-51-8P
	341522-53-0P	341522-55-2P	341522-57-4P	341522-59-6P 341522-61-0P
	341522-63-2P	341522-65-4P	341522-67-6P	341522-69-8P 341522-72-3P
	341522-74-5P	341522-96-1P	341523-09-9P	341523-13-5P 341523-15-7P
	RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (peptides having antiangiogenic activity)			
IT	341522-27-8	341522-31-4	341522-33-6	341522-94-9 341522-98-3
	341523-03-3	341523-07-7	708208-86-0	708208-87-1 708208-88-2
	708208-89-3 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (peptides having antiangiogenic activity)			
IT	341522-17-6P	341522-19-8P	341522-21-2P	341522-23-4P 341522-25-6P

Searcher : Shears 571-272-2528

09/787436

341522-30-3P 341522-32-5P 341522-34-7P 341522-36-9P 341522-38-1P  
341522-40-5P 341522-42-7P 341522-44-9P 341522-46-1P 341522-48-3P  
341522-50-7P 341522-52-9P 341522-54-1P 341522-56-3P 341522-58-5P  
341522-60-9P 341522-62-1P 341522-64-3P 341522-66-5P 341522-68-7P  
341522-70-1P 341522-73-4P 341522-75-6P 341522-77-8P 341522-79-0P  
341522-81-4P 341522-83-6P 341522-85-8P 341522-87-0P 341522-89-2P  
341522-91-6P 341522-93-8P 341522-95-0P 341522-97-2P 341522-99-4P  
341523-04-4P 341523-08-8P 341523-10-2P 341523-14-6P 341523-16-8P  
708208-90-6P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptides having antiangiogenic activity)

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 3 OF 6 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 140:321722 MARPAT

TITLE: Preparation of peptide antiangiogenic drugs

INVENTOR(S): Henkin, Jack; Haviv, Fortuna; Bradley, Michael F.;  
Kalvin, Douglas M.; Schneider, Andrew J.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: U.S., 84 pp., Cont.-in-part of U.S. Ser. No. 316,888.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6716963	B1	20040406	US 1999-447226	19991122
US 6774211	B1	20040810	US 2001-833196	20010411

PRIORITY APPLN. INFO.:

US 1998-86536P	19980522
US 1999-126546P	19990326
US 1999-316888	19990521
US 1999-447226	19991122

AB Peptides A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10 (A0 is an acyl group; A10 is OH, an amino group, or an amino acid amide; A1-9 are amino acyl residues) or their pharmaceutically acceptable salts, esters, solvates, or prodrugs were prepared for the treatment of angiogenesis. Thus, N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-NHET was prepared by the solid-phase method and assayed for in vitro angiogenic activity (87.3 and 76.9% inhibition at 20 nM and 10 nM. resp.).

IC ICM C07K007-00

NCL 530328000

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1

ST peptide prepn antiangiogenic activity

IT Solid phase synthesis

(peptide; preparation of peptide antiangiogenic drugs)

IT Angiogenesis

Angiogenesis inhibitors

Antitumor agents

Neoplasm

(preparation of peptide antiangiogenic drugs)

Searcher : Shears 571-272-2528

IT Peptides, preparation

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of peptide antiangiogenic drugs)

IT	251579-31-4P	251579-32-5P	251579-33-6P	251579-34-7P	251579-35-8P
	251579-36-9P	251579-37-0P	251579-38-1P	251579-39-2P	251579-40-5P
	251579-41-6P	251579-42-7P	251579-43-8P	251579-44-9P	251579-45-0P
	251579-46-1P	251579-47-2P	251579-48-3P	251579-49-4P	251579-50-7P
	251579-51-8P	251579-52-9P	251579-53-0P	251579-54-1P	251579-55-2P
	251579-56-3P	251579-57-4P	251579-58-5P	251579-59-6P	251579-60-9P
	251579-61-0P	251579-62-1P	251579-63-2P	251579-64-3P	251579-65-4P
	251579-66-5P	251579-67-6P	251579-68-7P	251579-69-8P	251579-70-1P
	251579-71-2P	251579-72-3P	251579-73-4P	251579-74-5P	251579-75-6P
	251579-76-7P	251579-77-8P	251579-78-9P	251579-79-0P	251579-80-3P
	251579-81-4P	251579-82-5P	251579-83-6P	251579-84-7P	251579-85-8P
	251579-86-9P	251579-87-0P	251579-88-1P	251579-89-2P	251579-90-5P
	251579-91-6P	251579-92-7P	251579-93-8P	251579-94-9P	251579-95-0P
	251579-96-1P	251579-97-2P	251579-98-3P	251579-99-4P	251580-00-4P
	251580-01-5P	251580-02-6P	251580-03-7P	251580-04-8P	251580-05-9P
	251580-06-0P	251580-07-1P	251580-08-2P	251580-09-3P	251580-10-6P
	251580-11-7P	251580-12-8P	251580-13-9P	251580-14-0P	251580-15-1P
	251580-16-2P	251580-17-3P	251580-18-4P	251580-19-5P	251580-20-8P
	251580-21-9P	251580-22-0P	251580-23-1P	251580-24-2P	251580-25-3P
	251580-26-4P	251580-27-5P	251580-28-6P	251580-29-7P	251580-30-0P
	251580-31-1P	251580-32-2P	251580-33-3P	251580-34-4P	251580-35-5P
	251580-36-6P	251580-37-7P	251580-38-8P	251580-39-9P	251580-40-2P
	251580-41-3P	251580-42-4P	251580-43-5P	251580-44-6P	251580-45-7P
	251580-46-8P	251580-47-9P	251580-48-0P	251580-49-1P	251580-50-4P
	251580-51-5P	251580-52-6P	251580-54-8P	251580-55-9P	251580-57-1P
	251580-58-2P	251580-60-6P	251580-61-7P	251580-63-9P	251580-64-0P
	251580-66-2P	251580-67-3P	251580-69-5P	251580-70-8P	251580-72-0P
	251580-73-1P	251580-75-3P	251580-76-4P	251580-78-6P	251580-79-7P
	251580-81-1P	251580-82-2P	251580-84-4P	251580-85-5P	251580-87-7P
	251580-88-8P	251580-90-2P	251580-91-3P	251580-93-5P	251580-94-6P
	251580-96-8P	251580-97-9P	251580-99-1P	251581-00-7P	251581-02-9P
	251581-03-0P	251581-05-2P	251581-07-4P	251581-08-5P	251581-10-9P
	251581-11-0P	251581-13-2P	251581-14-3P	251581-15-4P	251581-16-5P
	251581-17-6P	251581-18-7P	251581-19-8P	251581-20-1P	251581-21-2P
	251581-22-3P	251581-23-4P	251581-24-5P	251581-25-6P	251581-26-7P
	251581-27-8P	251581-28-9P	251581-29-0P	251581-30-3P	251581-31-4P
	251581-32-5P	251581-33-6P	251581-34-7P	251581-35-8P	251581-36-9P
	251581-37-0P	251581-38-1P	251581-39-2P	251581-40-5P	251581-41-6P
	251581-42-7P	251581-43-8P	251581-44-9P	251581-45-0P	251581-46-1P
	251581-47-2P	251581-48-3P	251581-49-4P	251581-50-7P	251581-51-8P
	251581-52-9P	251581-53-0P	251581-54-1P	251581-55-2P	251581-56-3P
	251581-57-4P	251581-58-5P	251581-59-6P	251581-60-9P	251581-61-0P
	251581-62-1P	251581-63-2P	251581-64-3P	251581-65-4P	251581-66-5P
	251581-67-6P	251581-68-7P	251581-69-8P	251581-70-1P	251581-71-2P
	251581-72-3P	251581-73-4P	251581-74-5P	251581-75-6P	251581-76-7P
	251581-77-8P	251581-78-9P	251581-79-0P	251581-80-3P	251581-81-4P
	251581-82-5P	251581-83-6P	251581-84-7P	251581-85-8P	251581-86-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of peptide antiangiogenic drugs)

IT	251581-87-0P	251581-88-1P	251581-89-2P	251581-90-5P	251581-91-6P
	251581-92-7P	251581-93-8P	251581-94-9P	251581-95-0P	251581-96-1P
	251581-97-2P	251581-98-3P	251581-99-4P	251582-00-0P	251582-01-1P
	251582-02-2P	251582-03-3P	251582-04-4P	251582-05-5P	251582-06-6P
	251582-07-7P	251582-08-8P	251582-09-9P	251582-10-2P	251582-11-3P
	251582-12-4P	251582-13-5P	251582-14-6P	251582-15-7P	251582-16-8P
	251582-17-9P	251582-18-0P	251582-19-1P	251582-20-4P	251582-21-5P
	251582-22-6P	251582-23-7P	251582-24-8P	251582-25-9P	251582-26-0P
	251582-27-1P	251582-28-2P	251582-29-3P	251582-30-6P	251582-31-7P
	251582-32-8P	251582-33-9P	251582-34-0P	251582-35-1P	251582-36-2P
	251582-37-3P	251582-38-4P	251582-39-5P	251582-40-8P	251582-41-9P
	251582-42-0P	251582-43-1P	251582-44-2P	251582-45-3P	251582-46-4P
	251582-47-5P	251582-48-6P	251582-49-7P	251582-50-0P	251582-51-1P
	251582-52-2P	251582-53-3P	251582-54-4P	251582-55-5P	251582-56-6P
	251582-57-7P	251582-58-8P	251582-59-9P	251582-60-2P	251582-61-3P
	251582-62-4P	251582-63-5P	251582-64-6P	251582-65-7P	251582-66-8P
	251582-67-9P	251582-68-0P	251582-69-1P	251582-70-4P	251582-71-5P
	251582-72-6P	251582-73-7P	251582-74-8P	251582-75-9P	251582-76-0P
	251582-77-1P	251582-78-2P	251582-79-3P	251582-80-6P	251582-81-7P
	251582-82-8P	251582-83-9P	251582-84-0P	251582-85-1P	251582-86-2P
	251582-87-3P	251582-88-4P	251582-89-5P	251582-90-8P	251582-91-9P
	251582-92-0P	251582-93-1P	251582-94-2P	251582-95-3P	251582-96-4P
	251582-97-5P	251582-98-6P	251582-99-7P	251583-00-3P	251583-01-4P
	251583-02-5P	251583-03-6P	251583-04-7P	251583-05-8P	251583-06-9P
	251583-07-0P	251583-08-1P	251583-09-2P	251583-10-5P	251583-11-6P
	251583-12-7P	251583-13-8P	251583-14-9P	251583-15-0P	251583-16-1P
	251583-17-2P	251583-18-3P	251583-19-4P	251583-20-7P	251583-21-8P
	251583-22-9P	251583-23-0P	251583-24-1P	251583-25-2P	251583-26-3P
	251583-27-4P	251583-28-5P	251583-29-6P	251583-30-9P	251583-31-0P
	251583-32-1P	251583-33-2P	251583-34-3P	251583-35-4P	251583-36-5P
	251583-37-6P	251583-38-7P	251583-39-8P	251583-40-1P	251583-41-2P
	251583-42-3P	251583-43-4P	251583-44-5P	251583-45-6P	251583-46-7P
	251583-47-8P	251583-48-9P	251583-49-0P	251583-50-3P	251583-51-4P
	251583-52-5P	251583-53-6P	251583-54-7P	251583-55-8P	251583-56-9P
	251583-57-0P	251583-58-1P	251583-59-2P	251583-60-5P	251583-61-6P
	251583-62-7P	251583-63-8P	251583-64-9P	251583-65-0P	251583-66-1P
	251583-67-2P	251583-68-3P	251583-69-4P	251583-70-7P	251583-71-8P
	251583-72-9P	251583-73-0P	251583-74-1P	251583-75-2P	251583-76-3P
	251583-77-4P	251583-78-5P	251583-79-6P	251583-80-9P	251583-81-0P
	251583-82-1P	251583-83-2P	251583-84-3P	251583-85-4P	251583-86-5P
	251583-87-6P	251583-88-7P	251583-89-8P	251583-90-1P	251583-91-2P
	251583-92-3P	251583-93-4P	251583-96-7P	251583-97-8P	251583-98-9P
	251583-99-0P	251584-00-6P	251584-01-7P	251584-02-8P	251584-03-9P
	251584-04-0P	251584-05-1P	251584-06-2P	251584-07-3P	251584-08-4P
	251584-09-5P	251584-10-8P	251584-11-9P	251584-12-0P	251584-13-1P
	251584-14-2P	251584-15-3P	251584-16-4P	251584-17-5P	251584-18-6P
	251584-19-7P	251584-20-0P	251584-21-1P	251584-22-2P	251584-23-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

	(preparation of peptide antiangiogenic drugs)				
IT	251584-24-4P	251584-25-5P	251584-26-6P	251584-27-7P	251584-28-8P
	251584-29-9P	251584-30-2P	251584-31-3P	251584-32-4P	251584-33-5P
	251584-34-6P	251584-35-7P	251584-36-8P	251584-37-9P	251584-38-0P
	251584-39-1P	251584-40-4P	251584-41-5P	251584-42-6P	251584-43-7P
	251584-44-8P	251584-45-9P	251584-46-0P	251584-47-1P	251584-48-2P

251584-49-3P	251584-50-6P	251584-51-7P	251584-52-8P	251584-53-9P
251584-54-0P	251584-55-1P	251584-56-2P	251584-57-3P	251584-58-4P
251584-59-5P	251584-60-8P	251584-61-9P	251584-62-0P	251584-63-1P
251584-64-2P	251584-65-3P	251584-66-4P	251584-67-5P	251584-68-6P
251584-69-7P	251584-70-0P	251584-71-1P	251584-72-2P	251584-73-3P
251584-74-4P	251584-75-5P	251584-76-6P	251584-77-7P	251584-78-8P
251584-79-9P	251584-80-2P	251584-81-3P	251584-82-4P	251584-83-5P
251584-84-6P	251584-85-7P	251584-86-8P	251584-87-9P	251584-88-0P
251584-89-1P	251584-90-4P	251584-91-5P	251584-92-6P	251584-93-7P
251584-94-8P	251584-95-9P	251584-96-0P	251584-97-1P	251584-98-2P
251584-99-3P	251585-00-9P	251585-01-0P	251585-02-1P	251585-03-2P
251585-04-3P	251585-05-4P	251585-06-5P	251585-07-6P	251585-08-7P
251585-09-8P	251585-10-1P	251585-11-2P	251585-12-3P	251585-13-4P
251585-14-5P	251585-15-6P	251585-16-7P	251585-17-8P	251585-18-9P
251585-19-0P	251585-20-3P	251585-21-4P	251585-22-5P	251585-23-6P
251585-24-7P	251585-25-8P	251585-26-9P	251585-27-0P	251585-28-1P
251585-29-2P	251585-30-5P	251585-31-6P	251585-32-7P	251585-33-8P
251585-34-9P	251585-35-0P	251585-36-1P	251585-37-2P	251585-38-3P
251585-39-4P	251585-40-7P	251585-41-8P	251585-42-9P	251585-43-0P
251585-44-1P	251585-45-2P	251585-46-3P	251585-47-4P	251585-48-5P
251585-49-6P	251585-50-9P	251585-51-0P	251585-52-1P	251585-53-2P
251585-54-3P	251585-55-4P	251585-56-5P	251585-57-6P	251585-58-7P
251585-59-8P	251585-60-1P	251585-61-2P	251585-62-3P	251585-63-4P
251585-64-5P	251585-65-6P	251585-66-7P	251585-67-8P	251585-68-9P
251585-69-0P	251585-70-3P	251585-71-4P	251585-72-5P	251585-73-6P
251585-74-7P	251585-75-8P	251585-76-9P	251585-77-0P	251585-78-1P
251585-79-2P	251585-80-5P	251585-81-6P	251585-82-7P	251585-83-8P
251585-84-9P	251585-85-0P	251585-86-1P	251585-87-2P	251585-88-3P
251585-89-4P	251585-90-7P	251585-91-8P	251585-92-9P	251585-93-0P
251585-94-1P	251585-95-2P	251585-96-3P	251585-97-4P	251585-98-5P
251585-99-6P	251586-00-2P	251586-01-3P	251586-03-5P	251586-04-6P
251586-05-7P	251586-06-8P	251586-07-9P	251586-08-0P	251586-09-1P
251586-10-4P	251586-11-5P	251586-12-6P	251586-13-7P	251586-15-9P
251586-16-0P	251586-17-1P	251586-18-2P	251586-19-3P	251586-20-6P
251586-21-7P	251586-22-8P	251586-23-9P	251586-24-0P	251586-25-1P
251586-26-2P	251586-27-3P	251586-28-4P	251586-29-5P	251586-30-8P
251586-31-9P	251586-32-0P	251586-33-1P	251586-34-2P	251586-35-3P
251586-36-4P	251900-41-1P	677013-17-1P	677013-18-2P	677013-56-8P
677013-57-9P	677013-80-8P	677013-81-9P	677013-82-0P	677013-83-1P
677013-84-2P	677013-85-3P	677013-86-4P	677013-87-5P	677013-88-6P
677013-89-7P	677013-91-1P	677013-92-2P	677013-94-4P	677013-95-5P
677013-96-6P	677013-97-7P	677013-99-9P	677014-00-5P	677014-01-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide antiangiogenic drugs)

IT 677014-02-7P 677014-03-8P 677014-04-9P 677014-05-0P 677014-06-1P  
677014-07-2P 677014-08-3P 677014-09-4P 677019-57-7P 677021-09-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide antiangiogenic drugs)

IT 59-67-6, Nicotinic acid, reactions 79-09-4, Propionic acid, reactions  
88-14-2, 2-Furoic acid 107-92-6, Butanoic acid, reactions 109-85-3,  
2-Methoxyethylamine 138-59-0, Shikimic acid 142-62-1, Hexanoic acid,  
reactions 625-45-6, Methoxyacetic acid 2516-47-4,

09/787436

Cyclopropanemethanamine 3222-56-8, 2-Methylnicotinic acid 4442-85-7,  
2-Cyclohexylethylamine 5292-21-7, Cyclohexylacetic acid 5913-13-3, r  
1-Cyclohexylethylamine 7154-73-6, 1-(2-Aminoethyl)pyrrolidine  
16874-33-2, Tetrahydro-2-furoic acid 27578-60-5,  
1-(2-Aminoethyl)piperidine 101711-55-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of peptide antiangiogenic drugs)

IT 675886-06-3 675886-07-4 675886-08-5 675886-09-6

RL: PRP (Properties)

(unclaimed protein sequence; preparation of peptide antiangiogenic drugs)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 4 OF 6 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 135:5821 MARPAT

TITLE: Preparation of peptides having antiangiogenic activity

INVENTOR(S): Haviv, Fortuna; Henkin, Jack; Bradley, Michael F.;  
Kalvin, Douglas M.; Schneider, Andrew J.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001038347	A2	20010531	WO 2000-US32217	20001122
WO 2001038347	A3	20011129		
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2391386	AA	20010531	CA 2000-2391386	20001122
EP 1232183	A2	20020821	EP 2000-982219	20001122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2003530313	T2	20031014	JP 2001-540110	20001122
PRIORITY APPLN. INFO.:				
				US 1999-447225 19991122
				US 2000-709034 20001108
				WO 2000-US32217 20001122

AB Peptides Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 [Xaa1 is absent, H or an acyl group; Xaa2-Xaa10 represent certain amino acyl groups; Xaa11 is OH, an amino acid amide selected from D-alanylamine, D-alanylethylamine, azaglycylamine, glycylamine, glycylethylamine, sarcosylamine, serylamine, D-serylamine, a residue NH(CH<sub>2</sub>)<sub>s</sub>CHR<sub>3</sub>R<sub>4</sub> or NHR<sub>5</sub> [s = 0-8, R<sub>3</sub> = H, alkyl, 5- to 6-membered cycloalkyl; R<sub>4</sub> = H, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocyclyl, OH; R<sub>5</sub> = H, OH, cycloalkyl (with provisos)]] or their pharmaceutically acceptable salts were prepared for inhibiting angiogenesis. Thus, Ac-Sar-Gly-Lys(Ac)-D-Leu-Thr-Nva-Ile-Arg-Pro-NHET was prepared by the solid-phase method using Fmoc-protected amino acids. The synthesized peptides inhibited human endothelial cell migration by at least 50 % at concns. of 1 nM.

IC ICM C07K007-00

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1.

Searcher : Shears 571-272-2528



ST peptide prepn antiangiogenesis  
 IT Eye, disease  
     (diabetic retinopathy; preparation of peptides having antiangiogenic activity)  
 IT Eye, disease  
     (macula, degeneration; preparation of peptides having antiangiogenic activity)  
 IT Angiogenesis inhibitors  
     Antiarthritics  
     Antitumor agents  
     Psoriasis  
     (preparation of peptides having antiangiogenic activity)  
 IT Peptides, preparation  
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
     (preparation of peptides having antiangiogenic activity)  
 IT 341522-16-5P 341522-17-6P 341522-18-7P 341522-19-8P 341522-20-1P  
 341522-21-2P 341522-22-3P 341522-23-4P 341522-24-5P 341522-25-6P  
 341522-27-8P 341522-28-9P 341522-29-0P 341522-30-3P 341522-31-4P  
 341522-32-5P 341522-33-6P 341522-34-7P 341522-35-8P 341522-36-9P  
 341522-37-0P 341522-38-1P 341522-39-2P 341522-40-5P 341522-41-6P  
 341522-42-7P 341522-43-8P 341522-44-9P 341522-45-0P 341522-46-1P  
 341522-47-2P 341522-48-3P 341522-49-4P 341522-50-7P 341522-51-8P  
 341522-52-9P 341522-53-0P 341522-54-1P 341522-55-2P 341522-56-3P  
 341522-57-4P 341522-58-5P 341522-59-6P 341522-60-9P 341522-61-0P  
 341522-62-1P 341522-63-2P 341522-64-3P 341522-65-4P 341522-66-5P  
 341522-67-6P 341522-68-7P 341522-69-8P 341522-70-1P 341522-72-3P  
 341522-73-4P 341522-74-5P 341522-75-6P 341522-76-7P 341522-77-8P  
 341522-78-9P 341522-79-0P 341522-80-3P 341522-81-4P 341522-82-5P  
 341522-83-6P 341522-84-7P 341522-85-8P 341522-86-9P 341522-87-0P  
 341522-88-1P 341522-89-2P 341522-90-5P 341522-91-6P 341522-92-7P  
 341522-93-8P 341522-94-9P 341522-95-0P 341522-96-1P 341522-97-2P  
 341522-98-3P 341522-99-4P 341523-01-1P 341523-02-2P 341523-03-3P  
 341523-04-4P 341523-05-5P 341523-06-6P 341523-07-7P 341523-08-8P  
 341523-09-9P 341523-10-2P 341523-11-3P 341523-12-4P 341523-13-5P  
 341523-14-6P 341523-15-7P 341523-16-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
     (preparation of peptides having antiangiogenic activity)

L36 ANSWER 5 OF 6 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 132:23191 MARPAT  
 TITLE: Preparation of peptide antiangiogenic drugs  
 INVENTOR(S): Henkin, Jack; Haviv, Fortuna; Bradley, Michael F.;  
               Kalvin, Douglas M.; Schneider, Andrew J.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 223 pp.  
           CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Searcher : Shears 571-272-2528

```

-----
WO 9961476      A1  19991202      WO 1999-US11448  19990521
W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
    DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
    KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
    MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
    TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW:  GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
    ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
    CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2329250      AA  19991202      CA 1999-2329250  19990521
AU 9944075      A1  19991213      AU 1999-44075   19990521
AU 764277       B2  20030814
EP 1078002      A1  20010228      EP 1999-927091  19990521
R:   AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
    SI, FI, RO
TR 200003442    T2  20010321      TR 2000-200003442 19990521
BR 9910639      A   20020115      BR 1999-10639   19990521
JP 2002516342   T2  20020604      JP 2000-550879  19990521
NZ 507912       A   20021025      NZ 1999-507912  19990521
NO 2000005890   A   20010112      NO 2000-5890    20001121
BG 105064       A   20010831      BG 2000-105064  20001218
PRIORITY APPLN. INFO.:
US 1998-83745   19980522
US 1999-250574  19990216
US 1999-277466  19990326
WO 1999-US11448 19990521
AB  Peptides A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10 (A0 is H or an acyl group; A10
    is OH or an amino acid amide; A1-9 are amino acyl residues) or their
    pharmaceutically acceptable salts, esters, solvates, or prodrugs were
    prepared for the treatment of angiogenesis. Thus, N-Ac-Sar-Gly-Val-D-Ile-
    Thr-Nva-Ile-Arg-Pro-NHEt was prepared by the solid-phase method and assayed
    for in vitro angiogenic activity (87.3% at 20 nM and 76.9 at 10 nM).
IC  ICM C07K014-78
    ICS A61K038-39; G01N033-68
CC  34-3 (Amino Acids, Peptides, and Proteins)
    Section cross-reference(s): 1
ST  peptide prepn antiangiogenic activity
IT  Eye, disease
    (diabetic retinopathy; preparation of peptide antiangiogenic drugs)
IT  Eye, disease
    (macula, degeneration; preparation of peptide antiangiogenic drugs)
IT  Angiogenesis inhibitors
    Antiarthritics
    Antitumor agents
    Psoriasis
    (preparation of peptide antiangiogenic drugs)
IT  Peptides, preparation
    RL: BAC (Biological activity or effector, except adverse); BSU (Biological
    study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
    BIOL (Biological study); PREP (Preparation); USES (Uses)
    (preparation of peptide antiangiogenic drugs)
IT  251579-31-4P  251579-32-5P  251579-33-6P  251579-34-7P  251579-35-8P
    251579-36-9P  251579-37-0P  251579-38-1P  251579-39-2P  251579-40-5P
    251579-41-6P  251579-42-7P  251579-43-8P  251579-44-9P  251579-45-0P
    251579-46-1P  251579-47-2P  251579-48-3P  251579-49-4P  251579-50-7P
    251579-51-8P  251579-52-9P  251579-53-0P  251579-54-1P  251579-55-2P

```

251579-56-3P	251579-57-4P	251579-58-5P	251579-59-6P	251579-60-9P
251579-61-0P	251579-62-1P	251579-63-2P	251579-64-3P	251579-65-4P
251579-66-5P	251579-67-6P	251579-68-7P	251579-69-8P	251579-70-1P
251579-71-2P	251579-72-3P	251579-73-4P	251579-74-5P	251579-75-6P
251579-76-7P	251579-77-8P	251579-78-9P	251579-79-0P	251579-80-3P
251579-81-4P	251579-82-5P	251579-83-6P	251579-84-7P	251579-85-8P
251579-86-9P	251579-87-0P	251579-88-1P	251579-89-2P	251579-90-5P
251579-91-6P	251579-92-7P	251579-93-8P	251579-94-9P	251579-95-0P
251579-96-1P	251579-97-2P	251579-98-3P	251579-99-4P	251580-00-4P
251580-01-5P	251580-02-6P	251580-03-7P	251580-04-8P	251580-05-9P
251580-06-0P	251580-07-1P	251580-08-2P	251580-09-3P	251580-10-6P
251580-11-7P	251580-12-8P	251580-13-9P	251580-14-0P	251580-15-1P
251580-16-2P	251580-17-3P	251580-18-4P	251580-19-5P	251580-20-8P
251580-21-9P	251580-22-0P	251580-23-1P	251580-24-2P	251580-25-3P
251580-26-4P	251580-27-5P	251580-28-6P	251580-29-7P	251580-30-0P
251580-31-1P	251580-32-2P	251580-33-3P	251580-34-4P	251580-35-5P
251580-36-6P	251580-37-7P	251580-38-8P	251580-39-9P	251580-40-2P
251580-41-3P	251580-42-4P	251580-43-5P	251580-44-6P	251580-45-7P
251580-46-8P	251580-47-9P	251580-48-0P	251580-49-1P	251580-50-4P
251580-51-5P	251580-52-6P	251580-54-8P	251580-55-9P	251580-57-1P
251580-58-2P	251580-60-6P	251580-61-7P	251580-63-9P	251580-64-0P
251580-66-2P	251580-67-3P	251580-69-5P	251580-70-8P	251580-72-0P
251580-73-1P	251580-75-3P	251580-76-4P	251580-78-6P	251580-79-7P
251580-81-1P	251580-82-2P	251580-84-4P	251580-85-5P	251580-87-7P
251580-88-8P	251580-90-2P	251580-91-3P	251580-93-5P	251580-94-6P
251580-96-8P	251580-97-9P	251580-99-1P	251581-00-7P	251581-02-9P
251581-03-0P	251581-05-2P	251581-07-4P	251581-08-5P	251581-10-9P
251581-11-0P	251581-13-2P	251581-14-3P	251581-15-4P	251581-16-5P
251581-17-6P	251581-18-7P	251581-19-8P	251581-20-1P	251581-21-2P
251581-22-3P	251581-23-4P	251581-24-5P	251581-25-6P	251581-26-7P
251581-27-8P	251581-28-9P	251581-29-0P	251581-30-3P	251581-31-4P
251581-32-5P	251581-33-6P	251581-34-7P	251581-35-8P	251581-36-9P
251581-37-0P	251581-38-1P	251581-39-2P	251581-40-5P	251581-41-6P
251581-42-7P	251581-43-8P	251581-44-9P	251581-45-0P	251581-46-1P
251581-47-2P	251581-48-3P	251581-49-4P	251581-50-7P	251581-51-8P
251581-52-9P	251581-53-0P	251581-54-1P	251581-55-2P	251581-56-3P
251581-57-4P	251581-58-5P	251581-59-6P	251581-60-9P	251581-61-0P
251581-62-1P	251581-63-2P	251581-64-3P	251581-65-4P	251581-66-5P
251581-67-6P	251581-68-7P	251581-69-8P	251581-70-1P	251581-71-2P
251581-72-3P	251581-73-4P	251581-74-5P	251581-75-6P	251581-76-7P
251581-77-8P	251581-78-9P	251581-79-0P	251581-80-3P	251581-81-4P
251581-82-5P	251581-83-6P	251581-84-7P	251581-85-8P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of peptide antiangiogenic drugs)

IT	251581-86-9P	251581-87-0P	251581-88-1P	251581-89-2P	251581-90-5P
	251581-91-6P	251581-92-7P	251581-93-8P	251581-94-9P	251581-95-0P
	251581-96-1P	251581-97-2P	251581-98-3P	251581-99-4P	251582-00-0P
	251582-01-1P	251582-02-2P	251582-03-3P	251582-04-4P	251582-05-5P
	251582-06-6P	251582-07-7P	251582-08-8P	251582-09-9P	251582-10-2P
	251582-11-3P	251582-12-4P	251582-13-5P	251582-14-6P	251582-15-7P
	251582-16-8P	251582-17-9P	251582-18-0P	251582-19-1P	251582-20-4P
	251582-21-5P	251582-22-6P	251582-23-7P	251582-24-8P	251582-25-9P
	251582-26-0P	251582-27-1P	251582-28-2P	251582-29-3P	251582-30-6P
	251582-31-7P	251582-32-8P	251582-33-9P	251582-34-0P	251582-35-1P

251582-36-2P	251582-37-3P	251582-38-4P	251582-39-5P	251582-40-8P
251582-41-9P	251582-42-0P	251582-43-1P	251582-44-2P	251582-45-3P
251582-46-4P	251582-47-5P	251582-48-6P	251582-49-7P	251582-50-0P
251582-51-1P	251582-52-2P	251582-53-3P	251582-54-4P	251582-55-5P
251582-56-6P	251582-57-7P	251582-58-8P	251582-59-9P	251582-60-2P
251582-61-3P	251582-62-4P	251582-63-5P	251582-64-6P	251582-65-7P
251582-66-8P	251582-67-9P	251582-68-0P	251582-69-1P	251582-70-4P
251582-71-5P	251582-72-6P	251582-73-7P	251582-74-8P	251582-75-9P
251582-76-0P	251582-77-1P	251582-78-2P	251582-79-3P	251582-80-6P
251582-81-7P	251582-82-8P	251582-83-9P	251582-84-0P	251582-85-1P
251582-86-2P	251582-87-3P	251582-88-4P	251582-89-5P	251582-90-8P
251582-91-9P	251582-92-0P	251582-93-1P	251582-94-2P	251582-95-3P
251582-96-4P	251582-97-5P	251582-98-6P	251582-99-7P	251583-00-3P
251583-01-4P	251583-02-5P	251583-03-6P	251583-04-7P	251583-05-8P
251583-06-9P	251583-07-0P	251583-08-1P	251583-09-2P	251583-10-5P
251583-11-6P	251583-12-7P	251583-13-8P	251583-14-9P	251583-15-0P
251583-16-1P	251583-17-2P	251583-18-3P	251583-19-4P	251583-20-7P
251583-21-8P	251583-22-9P	251583-23-0P	251583-24-1P	251583-25-2P
251583-26-3P	251583-27-4P	251583-28-5P	251583-29-6P	251583-30-9P
251583-31-0P	251583-32-1P	251583-33-2P	251583-34-3P	251583-35-4P
251583-36-5P	251583-37-6P	251583-38-7P	251583-39-8P	251583-40-1P
251583-41-2P	251583-42-3P	251583-43-4P	251583-44-5P	251583-45-6P
251583-46-7P	251583-47-8P	251583-48-9P	251583-49-0P	251583-50-3P
251583-51-4P	251583-52-5P	251583-53-6P	251583-54-7P	251583-55-8P
251583-56-9P	251583-57-0P	251583-58-1P	251583-59-2P	251583-60-5P
251583-61-6P	251583-62-7P	251583-63-8P	251583-64-9P	251583-65-0P
251583-66-1P	251583-67-2P	251583-68-3P	251583-69-4P	251583-70-7P
251583-71-8P	251583-72-9P	251583-73-0P	251583-74-1P	251583-75-2P
251583-76-3P	251583-77-4P	251583-78-5P	251583-79-6P	251583-80-9P
251583-81-0P	251583-82-1P	251583-83-2P	251583-84-3P	251583-85-4P
251583-86-5P	251583-87-6P	251583-88-7P	251583-89-8P	251583-90-1P
251583-91-2P	251583-92-3P	251583-93-4P	251583-96-7P	251583-97-8P
251583-98-9P	251583-99-0P	251584-00-6P	251584-01-7P	251584-02-8P
251584-03-9P	251584-04-0P	251584-05-1P	251584-06-2P	251584-07-3P
251584-08-4P	251584-09-5P	251584-10-8P	251584-11-9P	251584-12-0P
251584-13-1P	251584-14-2P	251584-15-3P	251584-16-4P	251584-17-5P
251584-18-6P	251584-19-7P	251584-20-0P	251584-21-1P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of peptide antiangiogenic drugs)

IT	251584-22-2P	251584-23-3P	251584-24-4P	251584-25-5P	251584-26-6P
	251584-27-7P	251584-28-8P	251584-29-9P	251584-30-2P	251584-31-3P
	251584-32-4P	251584-33-5P	251584-34-6P	251584-35-7P	251584-36-8P
	251584-37-9P	251584-38-0P	251584-39-1P	251584-40-4P	251584-41-5P
	251584-42-6P	251584-43-7P	251584-44-8P	251584-45-9P	251584-46-0P
	251584-47-1P	251584-48-2P	251584-49-3P	251584-50-6P	251584-51-7P
	251584-52-8P	251584-53-9P	251584-54-0P	251584-55-1P	251584-56-2P
	251584-57-3P	251584-58-4P	251584-59-5P	251584-60-8P	251584-61-9P
	251584-62-0P	251584-63-1P	251584-64-2P	251584-65-3P	251584-66-4P
	251584-67-5P	251584-68-6P	251584-69-7P	251584-70-0P	251584-71-1P
	251584-72-2P	251584-73-3P	251584-74-4P	251584-75-5P	251584-76-6P
	251584-77-7P	251584-78-8P	251584-79-9P	251584-80-2P	251584-81-3P
	251584-82-4P	251584-83-5P	251584-84-6P	251584-85-7P	251584-86-8P
	251584-87-9P	251584-88-0P	251584-89-1P	251584-90-4P	251584-91-5P
	251584-92-6P	251584-93-7P	251584-94-8P	251584-95-9P	251584-96-0P

251584-97-1P	251584-98-2P	251584-99-3P	251585-00-9P	251585-01-0P
251585-02-1P	251585-03-2P	251585-04-3P	251585-05-4P	251585-06-5P
251585-07-6P	251585-08-7P	251585-09-8P	251585-10-1P	251585-11-2P
251585-12-3P	251585-13-4P	251585-14-5P	251585-15-6P	251585-16-7P
251585-17-8P	251585-18-9P	251585-19-0P	251585-20-3P	251585-21-4P
251585-22-5P	251585-23-6P	251585-24-7P	251585-25-8P	251585-26-9P
251585-27-0P	251585-28-1P	251585-29-2P	251585-30-5P	251585-31-6P
251585-32-7P	251585-33-8P	251585-34-9P	251585-35-0P	251585-36-1P
251585-37-2P	251585-38-3P	251585-39-4P	251585-40-7P	251585-41-8P
251585-42-9P	251585-43-0P	251585-44-1P	251585-45-2P	251585-46-3P
251585-47-4P	251585-48-5P	251585-49-6P	251585-50-9P	251585-51-0P
251585-52-1P	251585-53-2P	251585-54-3P	251585-55-4P	251585-56-5P
251585-57-6P	251585-58-7P	251585-59-8P	251585-60-1P	251585-61-2P
251585-62-3P	251585-63-4P	251585-64-5P	251585-65-6P	251585-66-7P
251585-67-8P	251585-68-9P	251585-69-0P	251585-70-3P	251585-71-4P
251585-72-5P	251585-73-6P	251585-74-7P	251585-75-8P	251585-76-9P
251585-77-0P	251585-78-1P	251585-79-2P	251585-80-5P	251585-81-6P
251585-82-7P	251585-83-8P	251585-84-9P	251585-85-0P	251585-86-1P
251585-87-2P	251585-89-4P	251585-91-8P	251585-93-0P	251585-95-2P
251585-97-4P	251585-99-6P	251586-01-3P	251586-03-5P	251586-05-7P
251586-07-9P	251586-09-1P	251586-11-5P	251586-13-7P	251586-15-9P
251586-16-0P	251586-17-1P	251586-18-2P	251586-19-3P	251586-20-6P
251586-21-7P	251586-22-8P	251586-23-9P	251586-24-0P	251586-25-1P
251586-26-2P	251586-27-3P	251586-28-4P	251586-29-5P	251586-30-8P
251586-32-0P	251586-33-1P	251586-34-2P	251586-35-3P	251586-36-4P
251900-41-1P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of peptide antiangiogenic drugs)

IT 59-67-6, Nicotinic acid, reactions 79-09-4, Propionic acid, reactions 88-14-2, 2-Furoic acid 107-92-6, Butanoic acid, reactions 109-85-3, 2-Methoxyethylamine 138-59-0, Shikimic acid 142-62-1, Hexanoic acid, reactions 625-45-6, Methoxyacetic acid 2516-47-4, Cyclopropanemethanamine 3222-56-8, 2-Methylnicotinic acid 4442-85-7, 2-Cyclohexylethylamine 5292-21-7, Cyclohexylacetic acid 5913-13-3, r 1-Cyclohexylethylamine 7154-73-6, 1-(2-Aminoethyl)pyrrolidine 16874-33-2, Tetrahydro-2-furoic acid 27578-60-5, 1-(2-Aminoethyl)piperidine 101711-55-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of peptide antiangiogenic drugs)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 6 OF 6 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 125:87217 MARPAT

TITLE: Preparation of polymer-bound luteinizing hormone releasing factor analogs with antitumor activity.

INVENTOR(S): Lovas, Sandor; Murphy, Richard F.; Toth, Geza; Kalnay, Adrienn; Gaal, Dezso; Palyi, Istvan; Turi, Gizella; Vincze, Borbala; Mezo, Imre; et al.

PATENT ASSIGNEE(S): Ukraine

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9604927	A1	19960222	WO 1995-US10054	19950809
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2173727	AA	19960222	CA 1995-2173727	19950809
AU 9533616	A1	19960307	AU 1995-33616	19950809
EP 728012	A1	19960828	EP 1995-930123	19950809
EP 728012	B1	20040218		
R: DE, FR, GB, IT				
JP 09508142	T2	19970819	JP 1995-507451	19950809
US 6664369	B1	20031216	US 2000-269954	20000727
PRIORITY APPLN. INFO.:			HU 1994-2328	19940810
			HU 1994-2329	19940810
			WO 1995-US10054	19950809
AB	YWuVzXrAk [Y = R3[CHR1CHR2CH(CO-)C(CO-)]nH; n = 10-400; 1 of R1, R2 = H, the other = 2-oxopyrrolidin-1-yl; R3 = polymerization-initiating group, preferably Me2CCN; W = OH (or alkali metal salt thereof); V = alkylamino, bond; X = amino acid, r oligopeptide; A = pharmacol. active polypeptide; r = 0 to 0.2n; k ≤ r; z = 0 to n-r; u = n to 2n-r] and nonpolymer-bound peptides, were prepared Thus, N-vinylpyrrolidone-maleic anhydride copolymer was stirred 3 h with H-Gly-Phe-Leu-Gly nitrophenyl ester and Et3N in DMF to give after aqueous hydrolysis poly(N-vinylpyrrolidone-maleic acid)-Gly-Phe-Leu-Gly nitrophenyl ester. The latter in DMF was stirred 24 h with Ac-D-Trp1,3,D-Cpa2,Lys5,[β-Asp(DEA)]6,D-Ala10-HGnRH and Et3N to give Ac-D-Trp1,3,D-Cpa2,Lys[poly(N-vinylpyrrolidone-maleic acid)-Gly-Phe-Leu-Gly-] 5,[β-Asp(DEA)]6,D-Ala10-HGnRH. The latter at 50 μM in MCF-7 cell cultures showed 93% inhibition of colony formation.			
IC	ICM A61K038-00			
	ICS C07K005-00; C07K007-00; C07K017-00			
CC	34-3 (Amino Acids, Peptides, and Proteins)			
	Section cross-reference(s): 1			
ST	gnrh analog polymer bound prepn anticancer			
IT	Immunostimulants			
	Neoplasm inhibitors			
	(preparation of polymer-bound GNRH analogs with antitumor activity)			
IT	Peptides, preparation			
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(polymer-bound, preparation of polymer-bound GNRH analogs with antitumor activity)			
IT	111-26-2DP, 1-Hexanamine, poly(N-vinylpyrrolidone-maleic acid)-bound 9034-40-6DP, Gnrh, analogs 178414-67-0DP, poly(N-vinylpyrrolidone-maleic acid)-bound 178414-68-1DP, poly(N-vinylpyrrolidone-maleic acid)-bound 178414-69-2DP, poly(N-vinylpyrrolidone-maleic acid)-bound 178414-70-5DP, poly(N-vinylpyrrolidone-maleic acid)-bound 178414-71-6DP,			

poly(N-vinylpyrrolidone-maleic acid)-bound 178414-72-7DP,  
 poly(N-vinylpyrrolidone-maleic acid)-bound 178414-73-8DP,  
 poly(N-vinylpyrrolidone-maleic acid)-bound 178414-74-9DP,  
 poly(N-vinylpyrrolidone-maleic acid)-bound 178414-75-0DP,  
 poly(N-vinylpyrrolidone-maleic acid)-bound 178414-76-1DP,  
 poly(N-vinylpyrrolidone-maleic acid)-bound 178414-77-2DP,  
 poly(N-vinylpyrrolidone-maleic acid)-bound 178414-78-3DP,  
 poly(N-vinylpyrrolidone-maleic acid)-bound 178414-80-7P 178414-82-9P  
 178414-83-0P 178414-85-2P 178414-86-3P 178414-87-4P 178414-89-6P  
 178414-90-9P 178414-95-4P 178414-96-5P 178414-97-6P 178414-98-7P  
 178414-99-8P 178415-00-4P 178415-01-5P 178415-02-6P 178415-03-7P  
 178415-04-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of polymer-bound GNRH analogs with antitumor activity)

IT 108-24-7, Acetic anhydride 111-26-2, 1-Hexanamine 2389-45-9,  
 BOC-Lys(Z)-OH 4530-20-5 5241-64-5 15761-39-4D, resin-bound  
 26837-56-9, N-Vinylpyrrolidone-maleic anhydride copolymer 52671-12-2  
 65360-23-8, SJ 1004 73821-97-3 84624-27-1 87565-51-3, MI-1544  
 147859-97-0, Luteinizing hormone-releasing factor III (Petromyzon marinus)  
 176429-96-2, MI-1892 178414-81-8 178414-84-1 178414-88-5  
 178414-91-0 178414-92-1 178414-93-2

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of polymer-bound GNRH analogs with antitumor activity)

IT 13111-35-8DP, poly(N-vinylpyrrolidone-maleic acid)-bound 102685-48-3DP,  
 poly(N-vinylpyrrolidone-maleic acid)-bound 178414-65-8DP,  
 poly(N-vinylpyrrolidone-maleic acid)-bound 178414-66-9DP,  
 poly(N-vinylpyrrolidone-maleic acid)-bound 178414-79-4P 178414-94-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of polymer-bound GNRH analogs with antitumor activity)

FILE 'MARPATPREV' ENTERED AT 13:00:37 ON 22 NOV 2004  
 L32 STR



# NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

MLEVEL IS CLASS AT 16 29

GGCAT IS PCY AT 16

09/787436

GGCAT IS MCY UNS AT 29  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:  
ECLEVEL IS LIM ON ALL NODES  
ALL RING(S) ARE ISOLATED

L37 0 SEA FILE=MARPATPREV SSS FUL L32 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 12 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

L38 FILE 'REGISTRY' ENTERED AT 13:01:07 ON 22 NOV 2004  
4 S EHWSYL/SQSP

L38 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 581927-52-8 REGISTRY  
CN Protein (Klebsiella pneumoniae strain ATCC202080 clone  
US6610836-SEQID-13292 open reading frame-encoded) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2592: PN: US6610836 SEQID: 13292 claimed protein  
CI MAN  
SQL 573

SEQ 1 SPSRLRWVNS SPYFNREVFL QFDYIIIGAG SAGNVLATRL TEDPNTTVLL  
51 LEAGGPDYRF DFRTQMPAAL AYPLQGKRYN WAYETEPEPY MNNRMECGR  
101 GKGLGGSSLI NGMCYIRGNA MDLDNWAKEP GLEHWSYLDL LPYYRKAETR  
=====

151 DIGPNDYHGG DGPVSVTPPK PGNNPLFEAM VEAGVQAGYP RTDDLNGYQQ  
201 EGFGPMDRTV TPQGRRASTA RGYLDQARGR PNLTIRTHAL TDHIIIFAGKR  
251 AVGVWELEGE STIPSKATAN KEVLLCAGAI ASPQILQRSG VGNPELLRQF  
301 DIPVVHDLPG VGENLQDHLE MYLQYECKEP VSLYPALQWW NQPKIGAEWL  
351 FGGTGIGASN QFEAGGFIRS RAEFAWPNIQ YHFLPVAINY NGSNAVKEHG  
401 FQCHVGSMRS PSRGHVRLKS RDPHAHPAIL FNYMSHEQDW QEFRDAIRIT  
451 REIMNQPALD KYRGREISPG IECQSDAELD EFVRNHAETA FHPCGTCKMG  
501 YDEMAVVDGE GRVHGLEGLR VVDASIMPQI ITGNLNATTI MIGEKMAIDAI  
551 RGRQPLPRST ATYYVAGDAP VRR

HITS AT: 133-138

REFERENCE 1: 139:192571

L38 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 477074-93-4 REGISTRY  
CN Protein (Klebsiella pneumoniae clone KPN304388 essential) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2036: PN: WO02077183 SEQID: 60036 claimed protein  
CI MAN  
SQL 554

Searcher : Shears 571-272-2528



09/787436

SEQ 1 MQFDYIIIGA GSAGNVLATR LTEDPNTTVL LLEAGGPDYR FDFRTQMPAA  
51 LAYPLQ GKRY NWAYETEPEP YMNNRRMECG RGKGLGGSSL INGMCIYIRGN  
101 AMDLDNWAKE PGLEHWSYLD CLPYRKAET RDIGPN DYHG GDGPVSVTTP  
=====  
151 KPGNNPLFEA MVEAGVQAGY PRTDDLNGYQ QEGFGPMDRT VTPQGRRAST  
201 ARGYLDQARG RPNLTIRTHA LTDHII FAGK RAVGVEWLEG ESTIPSKATA  
251 NKEVLLCAGA IASPQILQRS GVGNPPELLRQ FDIPVVHDLP GVGENLQDHL  
301 EMYLQYECKE PVSLYPALQW WNQPKIGAEW LFGGTGIGAS NQFEAGGFIR  
351 SRAEFAWPNI QYHFLPVAIN YNGSNAVKEH GFQCHVGSMR SPSRGHVRLK  
401 SRDPHAHPAI LFNYSHEQD WQEFRDAIRI TREIMNQPAL DKYRGREISP  
451 GIECQSDAEL DEFVRNHAET AFHPCGTCKM GYDEMAVVDG EGRVHGLEGL  
501 RVVDASIMPQ IITGNLNATT IMIGEKMADA IRGRQPLPRS TATYYVAGDA  
551 PVRR

HITS AT: 114-119

REFERENCE 1: 138:1095

L38 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN

RN 465609-93-2 REGISTRY

CN Protein (Plasmodium falciparum strain 3D7 gene PF10-0219) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AAN35416

CN GenBank AAN35416 (Translated from: GenBank AE014832)

CI MAN

SQL 891

SEQ 1 MVKKDKKSKE KKEKLKLLKE KQKLKSLKSK KKKKDTLSDE DFDTICLYYE  
51 NLNKKDKFGH ININTTSNNT FVECEKPSPR SNCSITFIND EEFILFGGEY  
101 NDNNELISYN DLFKYNIVKN KWKYFTTSK KPKPRCSHOT VYFNKKLYIF  
151 GGELCTNTQF FHYNDFWSFD LKNNVFEEIE TKNKKDDNKP SPRSGHRMIL  
201 WKNYIVMFGG FFDNGKSIEY FNDLYIYIIN SNIWINLTNV YMDSLFRILT  
251 ENNSSNNDNN LSISSEKKKD LNKGKNSQIL KSKFFKNFDL DSFMPKSRSS  
301 VCLFTDMKYQ KIYIYGYSQ IKNTTRNAIG FYFNDMWILN INLINEDNIS  
351 VNFKKLKKSI FQPCKRTGFS TCIYKNSLIL FGGVFDKKVE NNSKKIDNPN  
401 NNNNMLEESL NLKSLFFNDL YLFDMNKEHW SYLNIKDKKE TKELNKTSA  
=====  
451 NKKNHKELEE NKIGTNIKKD KFQQMEREIY YEENNNNNNN NNNNKTQSKY  
501 EETSDGHVSS CFSDDNDEDY YSNVFVYFDE NGKRQIIKIE KEEKNKSSYN  
551 EKKDFDDVLK VEENNDYLNH SLDEEKNNI DKLIDNHSVF LQTKDIITG  
601 NGNKVTKIFG DENKHCQNIS NLPLNETILY VPLNNTTNSE NFMYSQELND  
651 STNMIKVEHI NDTENVDEET CKEDSVDEDM KDNSNSDSDS NKEEKKKKFV  
701 ISEEEPIGRI NSHIFVLNKN LYVYGMYEY KNNEIILSDY WKINIFKREK  
751 WELLDKGNLD DIYLEESDMS STISINDDDK DEKEIEDLII CSKIKKLEKK  
801 IKELDEGLAL DIKENLNEFF LRTKDHWLKE LNKISETKEI RKEAFYLC EQ  
851 KYKVIKKYYN KIQYKELLM EDDEERSISE TISSEQEQSS N

HITS AT: 428-433

REFERENCE 1: 137:289734

L38 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN

RN 112642-13-4 REGISTRY

CN Luteinizing hormone-releasing factor (swine), 1-L-glutamic acid-6-D-leucine-9- (N-ethyl-L-prolinamide)-10-deglycinamide- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

Searcher : Shears 571-272-2528

09/787436

CN Luteinizing hormone-releasing factor (pig), 1-L-glutamic  
acid-6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-  
SQL 9

SEQ 1 EHWSYLLRP

=====

HITS AT: 1-6

REFERENCE 1: 108:82207

FILE 'CAPLUS' ENTERED AT 13:01:52 ON 22 NOV 2004

L39 4 S L38

L40 3 S L39 NOT L28

L40 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 07 Sep 2003

ACCESSION NUMBER: 2003:697220 CAPLUS

DOCUMENT NUMBER: 139:192571

TITLE: Nucleic acid and encoded amino acid sequences relating  
to Klebsiella pneumoniae for diagnostics and  
therapeutics

INVENTOR(S): Breton, Gary L.; Osborne, Mark

PATENT ASSIGNEE(S): Genome Therapeutics Corporation, USA

SOURCE: U.S., 932 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6610836	B1	20030826	US 2000-489039	20000127
PRIORITY APPLN. INFO.:			US 1999-117747P	P 19990129

AB The invention provides 7171 isolated polypeptide and 7171 genomic nucleic acid sequences derived from Klebsiella pneumoniae strain 93,19097 (ATCC 202080) that are useful in diagnosis and therapy of pathol. conditions. The nucleotide sequences include those of two naturally occurring plasmids in K. pneumoniae. Antibodies against the polypeptides, and methods for the production of recombinant polypeptides are also provided. The invention also provides methods for the detection, prevention, and treatment of pathol. conditions resulting from bacterial infection. [This abstract record is one of four records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 581927-52-8

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; nucleic acid and encoded amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics)

L40 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 14 Oct 2002

ACCESSION NUMBER: 2002:781491 CAPLUS

DOCUMENT NUMBER: 138:1095

TITLE: Essential genes in microorganisms and their use as

Searcher : Shears 571-272-2528

targets for antisense inhibition of proliferation and antibiotic screening

INVENTOR(S): Wang, Liangus; Zamudio, Carlos; Malone, Cheryl; Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.; Yamamoto, Robert; Forsyth, R. Allyn; Xu, H. Howard

PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 1766 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002077183	A2	20021003	WO 2002-XN9107	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002061569	A1	20020523	US 2001-815242	20010321
WO 2002077183	A2	20021003	WO 2002-US9107	20020321
W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2001-815242	A 20010321
			US 2001-948993	A 20010906
			US 2001-342923P	P 20011025
			US 2002-72851	A 20020208
			US 2002-362699P	P 20020306
			WO 2002-US9107	A 20020321
			US 2000-191078P	P 20000321
			US 2000-206848P	P 20000523
			US 2000-207727P	P 20000526
			US 2000-242578P	P 20001023
			US 2000-253625P	P 20001127
			US 2000-257931P	P 20001222
			US 2001-269308P	P 20010216

AB The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified for which expression inhibits proliferation or is required for proliferation in *Enterococcus faecalis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, and

*Staphylococcus aureus*. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than *Staphylococcus aureus*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms. [This abstract record is one of twenty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 477074-93-4

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

L40 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ED Entered STN: 04 Oct 2002

ACCESSION NUMBER: 2002:752115 CAPLUS

DOCUMENT NUMBER: 137:289734

TITLE: Sequence of *Plasmodium falciparum* chromosomes 2, 10, 11 and 14

AUTHOR(S): Gardner, Malcolm J.; Shallom, Shamira J.; Carlton, Jane M.; Salzberg, Steven L.; Nene, Vishvanath; Shoaibi, Azadeh; Ciecko, Anne; Lynn, Jeffery; Rizzo, Michael; Weaver, Bruce; Jarrahi, Behnam; Brenner, Michael; Parvizi, Babak; Tallon, Luke; Moazzez, Azita; Granger, David; Fujii, Claire; Hansen, Cheryl; Pederson, James; Feldblyum, Tamara; Peterson, Jeremy; Suh, Bernard; Angiuoli, Sam; Perte, Mihaela; Allen, Jonathan; Selengut, Jeremy; White, Owen; Cummings, Leda M.; Smith, Hamilton O.; Adams, Mark D.; Venter, J. Craig; Carucci, Daniel J.; Hoffman, Stephen L.; Fraser, Claire M.

CORPORATE SOURCE: The Institute for Genomic Research, Rockville, MD, 20850, USA

SOURCE: Nature (London, United Kingdom) (2002), 419(6906), 531-534

CODEN: NATUAS; ISSN: 0028-0836

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The mosquito-borne malaria parasite *Plasmodium falciparum* kills an estimated 0.7-2.7 million people every year, primarily children in sub-Saharan Africa. Without effective interventions, a variety of factors-including the spread of parasites resistant to antimalarial drugs and the increasing insecticide resistance of mosquitoes-may cause the number of malaria cases to

09/787436

double over the next two decades. To stimulate basic research and facilitate the development of new drugs and vaccines, the genome of *Plasmodium falciparum* clone 3D7 has been sequenced using a chromosome-by-chromosome shotgun strategy. This report describes nucleotide sequences of chromosomes 10, 11 and 14, and a re-anal. of the chromosome 2 sequence. These chromosomes represent about 35% of the 23-megabase *P. falciparum* genome. The sequences are deposited in GenBank/EMBL/DDBJ under accession nos. AE001362.2 (chromosome 2), AE014185 (chromosome 10), AE014186 (chromosome 11), and AE014187 (chromosome 14).

IT 465609-93-2

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; complete sequence of *Plasmodium falciparum* chromosomes 2, 10, 11 and 14)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

(FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 13:02:33 ON 22 NOV 2004)

L41 0 S L38

FILE 'HOME' ENTERED AT 13:02:41 ON 22 NOV 2004

Searcher : Shears 571-272-2528